Profile data is unavailable for this security.
About the company
Aprea Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on precision oncology through synthetic lethality. The Company’s pipeline includes two clinical-stage synthetic lethality programs. Its lead programs are APR-1051, an oral, small-molecule inhibitor of WEE1 kinase, and ATRN-119, a small-molecule ATR inhibitor, both in clinical development for solid tumor indications. Its ATRN-119 is an oral small molecule inhibitor of ataxia telangiectasia and Rad3-related (ATR). The ATR kinase is a master regulator of Deoxyribonucleic Acid (DNA) damage response, with roles in cell cycle control and DNA repair following replication stress. It is evaluating potential combination opportunities within its pipeline, including research on the combination of ATRN-119 and APR-1051 that is supported by a Phase II SBIR grant from the National Cancer Institute. It also has an early-stage program, in the lead optimization stage, for an undisclosed DNA-damage response (DDR) target.
- Revenue in USD (TTM)488.24k
- Net income in USD-13.04m
- Incorporated2019
- Employees8.00
- LocationAprea Therapeutics Inc3805 OLD EASTON ROADDOYLESTOWN 18902United StatesUSA
- Phone+1 (215) 948-4119
- Fax+1 (302) 655-5049
- Websitehttps://www.aprea.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Quince Therapeutics Inc | 0.00 | -56.98m | 5.50m | 36.00 | -- | 5.08 | -- | -- | -1.22 | -1.22 | 0.00 | 0.0194 | 0.00 | -- | -- | 0.00 | -48.20 | -42.95 | -55.60 | -46.33 | -- | -- | -- | -- | -- | -- | 0.943 | -- | -- | -- | -81.07 | -- | 36.12 | -- |
| Calidi Biotherapeutics Inc | 0.00 | -25.62m | 5.61m | 28.00 | -- | 0.7806 | -- | -- | -9.62 | -9.62 | 0.00 | 1.00 | 0.00 | -- | -- | 0.00 | -194.84 | -- | -1,279.90 | -- | -- | -- | -- | -- | -- | -58.24 | 0.1544 | -- | -- | -- | 18.49 | -- | -- | -- |
| VivoSim Labs Inc | 142.00k | -1.23m | 5.74m | 5.00 | 2.06 | 1.29 | -- | 40.41 | 1.07 | 1.07 | 0.0608 | 1.70 | 0.0263 | -- | 4.81 | 10,923.08 | -22.71 | -51.63 | -45.51 | -56.47 | 100.00 | -- | -864.08 | -2,952.99 | -- | -- | 0.00 | -- | 32.11 | -42.01 | 83.04 | -- | -- | -- |
| Silexion Therapeutics Corp | 0.00 | -9.25m | 5.76m | 11.00 | -- | 0.7753 | -- | -- | -25.21 | -25.21 | 0.00 | 2.23 | 0.00 | -- | -- | 0.00 | -125.80 | -- | -221.96 | -- | -- | -- | -- | -- | -- | -84.50 | 0.1808 | -- | -- | -- | -223.39 | -- | -- | -- |
| Xenetic Biosciences Inc | 2.86m | -3.16m | 5.84m | 2.00 | -- | 0.9945 | -- | 2.04 | -2.05 | -2.05 | 1.85 | 2.57 | 0.436 | -- | -- | 1,429,470.00 | -48.14 | -42.99 | -57.42 | -46.44 | -- | -- | -110.40 | -373.71 | -- | -- | 0.00 | -- | -1.56 | 171.11 | 4.22 | -- | -- | -- |
| Aprea Therapeutics Inc | 488.24k | -13.04m | 6.19m | 8.00 | -- | 0.485 | -- | 12.68 | -2.14 | -2.14 | 0.08 | 1.95 | 0.0237 | -- | -- | 61,030.00 | -63.27 | -81.97 | -74.72 | -94.17 | -- | -- | -2,670.56 | -11,051.52 | -- | -- | 0.00 | -- | 157.63 | -- | 9.30 | -- | -12.91 | -- |
| Creative Medical Technology Holdings Inc | 6.00k | -5.96m | 6.26m | 4.00 | -- | 0.8261 | -- | 1,042.58 | -2.87 | -2.87 | 0.0027 | 2.17 | 0.0009 | 1.10 | -- | 1,500.00 | -93.58 | -83.62 | -98.14 | -- | 60.00 | 62.58 | -99,356.66 | -10,541.10 | 20.70 | -- | 0.00 | -- | 22.22 | -41.85 | -3.91 | -- | -- | -- |
| BioNexus Gene Lab Corp | 9.47m | -2.30m | 6.26m | 30.00 | -- | 0.6985 | -- | 0.6618 | -1.28 | -1.28 | 5.27 | 3.79 | 1.02 | 6.73 | 6.42 | -- | -24.68 | -6.00 | -27.80 | -7.75 | 14.77 | 14.31 | -24.27 | -4.98 | 6.81 | -1,354.05 | 0.00 | -- | -2.66 | 137.09 | 39.20 | -- | 77.67 | -- |
| Moleculin Biotech Inc | 0.00 | -41.36m | 6.41m | 17.00 | -- | -- | -- | -- | -55.88 | -55.88 | 0.00 | -13.60 | 0.00 | -- | -- | 0.00 | -189.07 | -49.52 | -254.72 | -54.93 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 26.89 | -- | -24.21 | -- |
| Bullfrog AI Holdings Inc | 116.67k | -6.76m | 6.59m | 9.00 | -- | 3.10 | -- | 56.51 | -0.6936 | -0.6936 | 0.0119 | 0.1866 | 0.0319 | -- | -- | 12,963.33 | -184.34 | -- | -233.50 | -- | 18.76 | -- | -5,770.66 | -- | -- | -- | 0.0278 | -- | -100.00 | -- | -31.42 | -- | -- | -- |
| enVVeno Medical Corp | 0.00 | -21.97m | 6.68m | 37.00 | -- | 0.1999 | -- | -- | -37.84 | -37.84 | 0.00 | 50.98 | 0.00 | -- | -- | 0.00 | -53.09 | -52.36 | -56.24 | -55.28 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 7.22 | -- | -36.69 | -- |
| Biomx Inc | 0.00 | -36.20m | 6.81m | 20.00 | -- | -- | -- | -- | -23.69 | -23.69 | 0.00 | -0.817 | 0.00 | -- | -- | 0.00 | -147.70 | -62.93 | -210.64 | -78.33 | -- | -- | -- | -- | -- | -41.56 | -- | -- | -- | -- | -104.20 | -- | -71.20 | -- |
| Aptorum Group Ltd | -100.00bn | -100.00bn | 6.88m | 1.00 | -- | 0.2679 | -- | -- | -- | -- | -- | 3.15 | -- | -- | -- | -- | -- | -33.06 | -- | -31.53 | -- | 1.65 | -- | -1,009.86 | -- | -- | 0.2079 | -- | -100.00 | -- | -51.09 | -- | -- | -- |
| Pulmatrix Inc | 0.00 | -5.16m | 6.90m | 2.00 | -- | 1.81 | -- | -- | -1.41 | -1.41 | 0.00 | 1.04 | 0.00 | -- | -- | 0.00 | -73.31 | -41.17 | -80.51 | -46.40 | -- | -- | -- | -257.55 | -- | -- | 0.00 | -- | -100.00 | -- | 46.00 | -- | -- | -- |
Data as of Mar 02 2026. Currency figures normalised to Aprea Therapeutics Inc's reporting currency: US Dollar USD
22.32%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| AIGH Capital Management LLCas of 31 Dec 2025 | 370.54k | 5.30% |
| Murchinson Ltd.as of 31 Dec 2025 | 340.14k | 4.86% |
| Sphera Funds Management Ltd.as of 31 Dec 2025 | 270.00k | 3.86% |
| Nantahala Capital Management LLCas of 31 Dec 2025 | 205.76k | 2.94% |
| DRW Securities LLCas of 31 Dec 2025 | 120.65k | 1.73% |
| Morgan Stanley & Co. LLCas of 31 Dec 2025 | 76.95k | 1.10% |
| Citadel Securities LLCas of 31 Dec 2025 | 51.04k | 0.73% |
| Jane Street Capital LLCas of 31 Dec 2025 | 46.62k | 0.67% |
| Geode Capital Management LLCas of 31 Dec 2025 | 40.95k | 0.59% |
| Vanguard Fiduciary Trust Co.as of 31 Dec 2025 | 38.46k | 0.55% |
More ▼
Data from 31 Dec 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
